Author: GLaD

New research raises concerns about hepatitis C post-cure life
We are pleased to announce the next publication from our ARC-funded project, ‘Addressing hepatitis C-related legal, policy and practice discrimination in a post-cure world’. Co-authored by GLaD program lead Kate Seear, with Suzanne Fraser, Sean Mulcahy, Dion Kagan, Emily Lenton, Adrian Farrugia and kylie valentine, and published in the international journal Social and Legal Studies, […]
Read More
Talking drugs, dance and human rights at the Global Meeting on Law and Society
GLaD project officer Sean Mulcahy recently presented a paper co-authored with project lead Kate Seear at the Global Meeting on Law and Society in Lisbon.
Read More
Australia’s national hepatitis C strategy must address post-cure lives
The Australian Department of Health will soon embark on developing the sixth iteration of the national hepatitis C strategy, anticipated to be its last, and firmly upholding the strategy of setting targets aligned with the global goal of eliminating hepatitis C as a public health concern by 2030.[1] Australia was one of the first countries […]
Read More
Forum explores the complex links between stigma and the law
The GLaD program was delighted to be invited to participate in the UNSW Centre for Social Health Research series ‘Spotlight on Stigma’, in April 2022. The ‘Spotlight on Stigma’ series, led by UNSW Professor Carla Treloar, has been running since 2021 and involves a series of forums focussing on stigma, blood-borne viruses and sexually transmitted […]
Read More
Drug policy landscapes: Understanding human rights imaginaries and drug policy in Colombia
Global discussion about human rights in drug policy reform is increasing. There are several studies that advocate for the need for human rights in drug policy. This advocacy often tends to describe how human rights and drug policy have intersected in the past, or makes a case for reforming drug policy through greater engagement with […]
Read More
New research on how human rights processes manage alcohol, other drugs and gender
We are excited to announce the publication of the first article from the ARC-funded project, ‘A world-first “post-human rights” framework for drug policy’. Co-authored by GLaD program lead Kate Seear and project officer Sean Mulcahy, the article is titled ‘Enacting safety and omitting gender: Australian human rights scrutiny processes concerning alcohol and other drug laws’. […]
Read More
Forum hears call for action on drugs, health and human rights
Each year, the United Nations celebrates two important, interconnected days on its international calendar. The 10th of December marks International Human Rights Day. In 2021, the theme is ‘Equality’. Two days later, on the 12th of December, the UN will celebrate Universal Health Coverage Day. On this day, we acknowledge the importance of strong, equitable […]
Read More
The launch of the Global Drug Policy Index
GLaD program lead Kate Seear recently joined colleagues from around Australia for a special panel event to mark the launch of the inaugural Global Drug Policy Index. The Index measures and compares national-level drug policies, including their implementation, against the UN’s Common Position on Drugs. The Index assesses and ranks the performance of countries across […]
Read More
Critical drug scholarship as an otherwise to rights
GLaD program lead Kate Seear and project officer Sean Mulcahy recently presented a paper at the After Rights? Politics, Ethics and Aesthetics Workshop.
Read More
Victorian inquiry into cannabis considers law reform
A Victorian parliamentary committee recently released a report detailing the findings and recommendations from a major inquiry into the use of cannabis in Victoria. GLaD program lead Associate Professor Kate Seear was one of several people to make a submission to the inquiry.
Read More
On International Overdose Awareness Day, new research considers post-mortem rights
Each year, on the 31st of August, people around the world come together to mark International Overdose Awareness Day. Initiated in 2001 by Melburnian Sally J Finn, International Overdose Awareness Day is an opportunity to pause, grieve, memorialise lives lost, and to stimulate frank conversations about overdose and other drug-related harms and how to prevent them.
Read More
Towards a new Mental Health and Wellbeing Act – considerations for human rights
The Royal Commission into Victoria’s Mental Health System delivered its final report in February of this year, and it was tabled in Parliament in March. Among the matters the Commission was appointed to consider was the need to address the stigma associated with mental health, and the need to safeguard human rights.
Read More
#HepCantWait, but the legacy effect of stigma and discrimination ‘doesn’t just go away’
Since late 2019, COVID-19 has been the global health crisis absorbing much of our attention. Efforts to respond to it, including the redeployment of people and resources, have necessarily had impacts on other public health programs and pandemics. The World Health Organization’s ambitious goal to eliminate hepatitis C by 2030 is one program that has been slowed and, in some places, stopped in its tracks by COVID-19.
Read More
The New South Wales Mandatory Disease Testing Act
The Mandatory Disease Testing Act 2021, recently passed through the New South Wales Parliament,establishes a new scheme under which a person can be ordered to provide a blood sample for the testing of blood-borne viruses if, as a result of their deliberate action, their bodily fluid has come into contact with a health, emergency or public sector worker.
Read More
Post-cure lives – now recruiting
Seeking participants for research on people’s lived experience of hepatitis C cure
Read More
Life after cure – preliminary findings from the post-cure project
What does life look like for people after they have cleared hepatitis C?
Read More
Life after cure – preliminary findings from the post-cure project
What does life look like for people after they have cleared hepatitis C? Do people whose blood shows no detectable amount of the hepatitis C virus need to inform their doctor or dentist about their previous hepatitis C status? What about prospective employers or insurance providers? Does hepatitis C–related stigma and discrimination remain a challenge for people post-cure? In what ways, and in what settings?
Read More